Antineoplaston Therapy in Treating Children With Primitive Neuroectodermal Tumors
Completed · Phase 2
Conditions studied: Childhood CNS Primitive Neuroectodermal Tumor
In brief
RATIONALE: Current therapies for children with primitive neuroectodermal tumors that have not responded to standard therapy provide very limited benefit to the patient. The anti-cancer properties of Antineoplaston therapy suggest that it may prove beneficial in the treatment of children with primitive neuroectodermal tumors that have not responded to standard therapy. PURPOSE: This study is being performed to determine the effects (good and bad) that Antineoplaston therapy has on children (\> 6 months of age) with primitive neuroectodermal tumors that has not responded to standard therapy.
Key facts
- Study ID
- NCT00003460
- Run by
- Burzynski Research Institute
- People needed
- 13
- Starts
- 1996-04-01
- Expected to finish
- 2005-02-01
- Last updated by the study team
- 2017-08-24
Who can join
Age: 1 and older, up to 17. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Burzynski Clinic — Houston, Texas, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.